Search research articles
Contact Us
Filters
Showing results (11-20 of 32) with videos related to
Page
of 4
Sort By:
Innovations in Clinical Neuroscience
|
March 3, 2018
Cognitive Impairment Associated with Cancer: A Brief Review
J Cara Pendergrass, Steven D Targum, John E Harrison
Journal of Alzheimer'S Disease : JAD
|
March 8, 2020
Cognitive Functions as Predictors of Alzheimer's Disease Biomarker Status in the European Prevention of Alzheimer's Dementia Cohort
Graciela Muniz Terrera, John E Harrison, Craig W Ritchie, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Drug Development
Jack Taylor, Paul Rolan, Mark Jaros, et al.
The Lancet. Psychiatry
|
June 5, 2016
Selection of cognitive tests for trials of therapeutic agents
John E Harrison, Raymond W Lam, Bernhard T Baune, et al.
Digital Biomarkers
|
November 30, 2020
Evaluation of Speech-Based Digital Biomarkers: Review and Recommendations
Jessica Robin, John E Harrison, Liam D Kaufman, et al.
NPJ Digital Medicine
|
June 5, 2025
Exploring the potential of digital biomarkers as a measure of brain health 'capital'
Dylan Powell, Stephanie A Adams, Donncha Mullin, et al.
Collegium Antropologicum
|
June 9, 2011
A validation study of appropriate phonological verbal fluency stimulus letters for use with croatian speaking individuals
Ninoslav Mimica, Danijela Zakić Milas, Svetislav Joka, et al.
Alzheimer'S Research & Therapy
|
May 28, 2021
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease
Niels D Prins, John E Harrison, Hui-May Chu, et al.
JMIR Formative Research
|
February 18, 2022
Asynchronous Remote Assessment for Cognitive Impairment: Reliability Verification of the Neurotrack Cognitive Battery
Jennifer Rae Myers, Jordan M Glenn, Erica N Madero, et al.
European Heart Journal
|
November 30, 2017
No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data
Philip D Harvey, Marwan N Sabbagh, John E Harrison, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 32) with videos related to
Sort By:
Page
of 4
Innovations in Clinical Neuroscience
|
March 3, 2018
Cognitive Impairment Associated with Cancer: A Brief Review
J Cara Pendergrass, Steven D Targum, John E Harrison
Journal of Alzheimer'S Disease : JAD
|
March 8, 2020
Cognitive Functions as Predictors of Alzheimer's Disease Biomarker Status in the European Prevention of Alzheimer's Dementia Cohort
Graciela Muniz Terrera, John E Harrison, Craig W Ritchie, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Drug Development
Jack Taylor, Paul Rolan, Mark Jaros, et al.
The Lancet. Psychiatry
|
June 5, 2016
Selection of cognitive tests for trials of therapeutic agents
John E Harrison, Raymond W Lam, Bernhard T Baune, et al.
Digital Biomarkers
|
November 30, 2020
Evaluation of Speech-Based Digital Biomarkers: Review and Recommendations
Jessica Robin, John E Harrison, Liam D Kaufman, et al.
NPJ Digital Medicine
|
June 5, 2025
Exploring the potential of digital biomarkers as a measure of brain health 'capital'
Dylan Powell, Stephanie A Adams, Donncha Mullin, et al.
Collegium Antropologicum
|
June 9, 2011
A validation study of appropriate phonological verbal fluency stimulus letters for use with croatian speaking individuals
Ninoslav Mimica, Danijela Zakić Milas, Svetislav Joka, et al.
Alzheimer'S Research & Therapy
|
May 28, 2021
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease
Niels D Prins, John E Harrison, Hui-May Chu, et al.
JMIR Formative Research
|
February 18, 2022
Asynchronous Remote Assessment for Cognitive Impairment: Reliability Verification of the Neurotrack Cognitive Battery
Jennifer Rae Myers, Jordan M Glenn, Erica N Madero, et al.
European Heart Journal
|
November 30, 2017
No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data
Philip D Harvey, Marwan N Sabbagh, John E Harrison, et al.
Page
of 4